Datar Genetics Limited

datarpgx.com

Datar Genetics Limited is a NABL and ISO 9001:2008 accredited Centre for Excellence in Genetics for providing innovative, comprehensive clinical management solutions in the domain of molecular genomics. We have fully integrated sequencing, bio-informatics, human interface and interpretation platforms with State of the Art technological capability to provide clinical applications. We provide the widest range of genetic solutions and analytics of 300+ high impact investigations across the domains of Oncology, Cardiology, Neurology, Diabetes, High Resolution HLA Typing and Matching, Reproductive Genetics, Neonatal Screening, Pharmacogenetics and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

news image

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More

Cell and Gene Therapy

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

Industrial Impact, Medical

MODERNA AND GENERATION BIO ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NON-VIRAL GENETIC MEDICINES

Accesswire | March 24, 2023

news image

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Generation Bio Co. a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application ...

Read More
news image

Research

CHEMISTRY42, AN AI SYSTEM FROM INSILICO, HAS BEEN INCORPORATED INTO UCB'S DRUG DISCOVERY PROGRAMMES

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and exp...

Read More
news image

Cell and Gene Therapy

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

Industrial Impact, Medical

MODERNA AND GENERATION BIO ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NON-VIRAL GENETIC MEDICINES

Accesswire | March 24, 2023

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Generation Bio Co. a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us